Open Call:
Therapeutics for New Drug Development
Commercialise Your Innovations with Celltrion, a Global Biopharma Leader
About Celltrion
​
Celltrion is a global biopharmaceutical leader with deep expertise in drug development and biologics manufacturing. The company is actively seeking innovations for new drug development to advance healthcare solutions. With a proven track record of successful collaborations, including partnerships with Pinot Bio and Abpro, Celltrion is eager to work with innovators who are ready to take their solutions to the next level.
This is your opportunity to collaborate with Celltrion through co-development, investment, licensing, and commercialisation pathways, bringing your breakthrough innovations to a global audience.
​
​​​Focus Area 1: Antibody Oncology Therapeutics
​
Celltrion is actively seeking cutting-edge oncology-focused antibody therapeutic innovations. We are particularly interested in novel approaches that leverage the power of antibody engineering to target cancer more effectively. This includes new antibody modalities, conjugate platforms, and next-generation targeted delivery systems.
​
​​​Problem Statement
​
Despite the advancement of antibody-based therapies, many oncology treatments still suffer from challenges in targeting specificity, resistance development, and systemic toxicity. There is a critical need for modular, next-generation antibody technologies that can overcome these limitations and offer durable, patient-centric solutions. Celltrion aims to bridge this gap by partnering with innovators who are developing scalable and clinically meaningful oncology therapeutics.
​
​
What We’re Looking For
1. Novel Antibody Therapeutics
-
Bi-specific, multi-specific, or first-in-class monoclonal antibodies targeting validated or novel cancer-related antigens.
-
Criteria/stage: In-vivo proof-of-concept (POC) data required
2. Antibody-Drug Conjugates (ADCs)
-
Innovations in payload design, conjugation technology, or linker chemistry.
-
Criteria/stage: In vivo efficacy data required
3. Advanced Antibody Conjugate Platforms
-
ARC (Antibody-Radionuclide Conjugates) for precise radiotherapeutic delivery
-
DAC (Degrader Antibody Conjugates) leveraging targeted protein degradation
-
PAC (PROTAC Antibody Conjugates) enabling degradation via antibody-guided PROTACs
-
Criteria/stage: In vivo efficacy data required
​​
​​
Deadline to Apply: 30 June 2025
​
Focus Area 2: Peptide-based Therapies
​
Celltrion is expanding its innovation landscape to include next-generation peptide-based therapies in either immunology or metabolic diseases, sarcopenia. We are actively scouting for advanced peptide technologies that address unmet medical needs through novel delivery methods, enhanced pharmacological profiles, and targeted therapeutic action.
​
​​
Problem Statement
​
Peptide-based therapies hold significant promises for precision treatment in both immunology and metabolic disorders. However, challenges such as short half-life, delivery limitations, and suboptimal safety profiles have hindered broad clinical adoption. Celltrion seeks to address these challenges by partnering with innovators developing differentiated peptide technologies with proven efficacy and strong translational potential.
​
​
What We’re Looking For
1. Immunology
-
Peptide Drug Conjugates: Peptide carriers conjugated to small molecules or biologically active agents for targeted immunomodulation.
-
Radionuclide Peptide Conjugates: Therapeutics that combine peptide specificity with radiotherapeutic precision to treat inflammatory or autoimmune disease.
-
Criteria/stage: In vivo efficacy data required
​
2. Metabolic Disease, Sarcopenia
-
Novel Peptide Therapeutics: New peptides that demonstrate improved safety and efficacy for treating muscle loss and functional decline in aging populations. Desired characteristics include extended half-life, oral bioavailability, time-release formulations (e.g., sustained micro-dosing tablets)
-
Criteria/stage: In vivo efficacy data required; supporting non-GLP or GLP toxicity data preferred
​​
​
Deadline to Apply: 30 June 2025
​
​​
​Focus Area 3: Nucleic Acid Therapeutics
​
Celltrion is seeking transformative innovations in nucleic acid therapeutics (NATs) to address critical unmet needs in oncology and metabolic diseases. We are particularly interested in siRNA, antisense oligonucleotides, and mRNA platforms designed to either inhibit or stimulate specific protein expression. Technologies that demonstrate improved efficacy, extended half-life, and optimised delivery are highly encouraged. ​
​​​​
​​​
Problem Statement
​​
Nucleic acid therapeutics have emerged as a powerful tool for precision medicine, yet challenges remain in delivery, durability, and off-target effects. Celltrion is seeking NAT platforms with optimised design and delivery characteristics that can overcome these hurdles in oncology and metabolic indications, with an emphasis on strong in vivo validation and clinical translation potential.
​​​
​​
What We’re Looking For
​
Technologies for oncology and metabolic diseases such as:
​
-
siRNA (Small Interfering RNA): Gene-silencing platforms targeting disease-driving genes with high specificity and efficiency.
-
Antisense Oligonucleotides (ASOs): Precision modulators of gene expression with improved chemical stability and delivery potential.
-
mRNA Therapeutics: Platforms that either suppress or indue protein expression for therapeutic effect, with innovations in delivery, translation efficiency, and immune tolerability.
-
Criteria/stage: In vivo efficacy data required; supporting non-GLP or GLP toxicity data preferred
​
​
Deadline to Apply: 30 June 2025
​
​
​Focus Area 4: Drug Delivery Systems
​
Celltrion is seeking cutting-edge drug delivery system (DDS) innovations that enable precise, tissue- or cell-selective therapeutic targeting in immunology and inflammatory disease. We are especially interested in lipid- and polymer-based nanoparticle platforms that enhance delivery efficiency, reduce systemic toxicity, and optimise therapeutic outcomes.
​​​
Problem Statement
While the therapeutic landscape in immunology and inflammation has expanded, current treatments often struggle with systemic side effects and poor localisation. There is a critical need for next-generation delivery platforms that offer targeted, controlled, and biocompatible solutions to improve the safety and effectiveness of immuno-therapeutics. Celltrion is looking to fill this gap through partnerships with innovators in drug delivery science.
​​​
​​
What We’re Looking For
Technologies for immunology and inflammatory diseases such as:
1. Tissue/Cell-Selective Delivery Systems: Platforms that achieve targeted accumulation at specific immune or inflammatory sites, reducing off-target effects and enhancing therapeutic efficiency.
2. Lipid- or Polymer-Based Nanoparticle Systems:
-
Lipid nanoparticles (LNPs) designed for mRNA, peptide, or small molecule encapsulation.
-
Biodegradable polymer-based nanoparticles with tunable release and targeting profiles.
-
Systems capable of sustained release or environmentally responsive delivery.
3. Criteria/stage: In vivo efficacy data required
​
​
Deadline to Apply: 30 June 2025
​
​​
​
.